On and off over the past few years your sitemaster has raised the question of whether there is any real clinical benefit to maintaining men on standard androgen deprivation therapy (ADT) once they become castrate resistant and are switched to treatment with newer drugs like abiraterone acetate (Zytiga) or enzalutamide (Xtandi). … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, ADT, androgen, castration-resistant, deprivation, mCRPC, metastatic, SPARE, trial | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 